000844885 001__ 844885
000844885 005__ 20220930130145.0
000844885 0247_ $$2doi$$a10.3390/ijms19041090
000844885 0247_ $$2ISSN$$a1422-0067
000844885 0247_ $$2ISSN$$a1661-6596
000844885 0247_ $$2Handle$$a2128/17954
000844885 0247_ $$2pmid$$apmid:29621181
000844885 0247_ $$2WOS$$aWOS:000434978700169
000844885 0247_ $$2altmetric$$aaltmetric:35753239
000844885 037__ $$aFZJ-2018-02231
000844885 041__ $$aEnglish
000844885 082__ $$a570
000844885 1001_ $$0P:(DE-HGF)0$$aCeccon, Garry$$b0
000844885 245__ $$aDabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation
000844885 260__ $$aBasel$$bMolecular Diversity Preservation International$$c2018
000844885 3367_ $$2DRIVER$$aarticle
000844885 3367_ $$2DataCite$$aOutput Types/Journal article
000844885 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1523262053_15730
000844885 3367_ $$2BibTeX$$aARTICLE
000844885 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000844885 3367_ $$00$$2EndNote$$aJournal Article
000844885 520__ $$aNovel therapeutic targets in malignant glioma patients are urgently needed. Point mutations of the v-Raf murine sarcoma viral oncogene homolog B (BRAF) gene occur predominantly in melanoma patients, but may also occur in gliomas. Thus, this is a target of great interest for this group of patients. In a nine-year-old male patient, an anaplastic astrocytoma in the left temporoparietal region was diagnosed histologically. After first- and second-line treatment, a malignant progression to a secondary glioblastoma was observed ten years after the initial diagnosis. Within the following seven years, all other conventional treatment options were exhausted. At this time point, recurrent tumor histology revealed an epithelioid glioblastoma, without a mutation in the isocitrate dehydrogenase gene (IDH wild-type). In order to identify a potential target for an experimental salvage therapy, mutational tumor analysis showed a BRAF V600E mutation. Consecutively, dabrafenib treatment was initiated. The patient remained clinically stable, and follow-up magnetic resonance images (MRI) were consistent with “Stable Disease” according to the Response Assessment in Neuro-Oncology Working Group (RANO) criteria for the following ten months until tumor progression was detected. The patient died 16 months after dabrafenib treatment initiation. Particularly in younger glioma patients as well as in patients with an epithelioid glioblastoma, screening for a V600E BRAF mutation is promising since, in these cases, targeted therapy with BRAF inhibitors seems to be a useful salvage treatment option.
000844885 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000844885 588__ $$aDataset connected to CrossRef
000844885 7001_ $$0P:(DE-HGF)0$$aWerner, Jan-Michael$$b1
000844885 7001_ $$0P:(DE-Juel1)156211$$aDunkl, Veronika$$b2
000844885 7001_ $$0P:(DE-Juel1)171739$$aTscherpel, Caroline$$b3$$ufzj
000844885 7001_ $$0P:(DE-Juel1)131627$$aStoffels, Gabriele$$b4$$ufzj
000844885 7001_ $$00000-0001-6233-8339$$aBrunn, Anna$$b5
000844885 7001_ $$0P:(DE-HGF)0$$aDeckert, Martina$$b6
000844885 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon Rudolf$$b7$$ufzj
000844885 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b8$$eCorresponding author$$ufzj
000844885 773__ $$0PERI:(DE-600)2019364-6$$a10.3390/ijms19041090$$gVol. 19, no. 4, p. 1090 -$$n4$$p1090 -$$tInternational journal of molecular sciences$$v19$$x1422-0067$$y2018
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.pdf
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.gif?subformat=icon$$xicon
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.jpg?subformat=icon-1440$$xicon-1440
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.jpg?subformat=icon-180$$xicon-180
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.jpg?subformat=icon-640$$xicon-640
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/Invoice_MDPI_ijms-288753_Galldiks.pdf?subformat=pdfa$$xpdfa
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.pdf$$yOpenAccess
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.gif?subformat=icon$$xicon$$yOpenAccess
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000844885 8564_ $$uhttps://juser.fz-juelich.de/record/844885/files/ijms-19-01090-1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000844885 8767_ $$8ijms-288753$$92018-04-05$$d2018-04-05$$eAPC$$jZahlung erfolgt$$pijms-288753
000844885 909CO $$ooai:juser.fz-juelich.de:844885$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000844885 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171739$$aForschungszentrum Jülich$$b3$$kFZJ
000844885 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b4$$kFZJ
000844885 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b7$$kFZJ
000844885 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b8$$kFZJ
000844885 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000844885 9141_ $$y2018
000844885 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000844885 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000844885 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000844885 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J MOL SCI : 2015
000844885 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000844885 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000844885 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000844885 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000844885 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000844885 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000844885 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000844885 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000844885 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000844885 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000844885 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000844885 920__ $$lyes
000844885 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000844885 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000844885 980__ $$ajournal
000844885 980__ $$aVDB
000844885 980__ $$aUNRESTRICTED
000844885 980__ $$aI:(DE-Juel1)INM-3-20090406
000844885 980__ $$aI:(DE-Juel1)INM-4-20090406
000844885 980__ $$aAPC
000844885 9801_ $$aAPC
000844885 9801_ $$aFullTexts